ImaginAb Announces First Patient Dosed in Australia in Phase IIb iPREDICT Trial
Los Angeles, California, USA, October 25th, 2022 – ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation radiopharmaceutical therapies (RPT) products, is pleased to announce that the first patient has been dosed at the Macquarie University Hospital in Sydney, Australia as part of its Phase IIb iPREDICT clinical trial.
ImaginAb announced the launch of its Phase IIb iPREDICT trial in January this year, which is a part of its clinical development to support marketing approval for CD8 ImmunoPET. iPREDICT is being conducted globally in the US, Australia, and Europe.
